ElectroCore Expands Intellectual Property Portfolio With U.S. Patent No. 11,894,148 Entitled "Systems And Methods For Treating Patients With Diseases Associated With Viruses"
ElectroCore Expands Intellectual Property Portfolio With U.S. Patent No. 11,894,148 Entitled "Systems And Methods For Treating Patients With Diseases Associated With Viruses"
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).
商业阶段的生物电子医学和健康公司ElectroCore, Inc.（纳斯达克股票代码：ECOR）今天宣布，美国专利商标局已颁发了一项与治疗冠状病毒家族（COVID）病毒相关疾病的系统和方法相关的专利。
U.S. Patent No. 11,894,148 entitled "Systems and Methods for Treating Patients With Diseases Associated With Viruses" generally relates to methods for treating disorders with viruses in the COVID family using electrical impulses transcutaneously to the vagus nerve for about 30 seconds to about 5 minutes, from 2 to 5 times per day, to reduce a level of C-reactive protein in the blood of the patient.
美国第11,894,148号专利，题为 “治疗与病毒相关的疾病的患者的系统和方法”，通常涉及使用经皮电脉冲迷走神经约30秒至约5分钟，每天2至5次，以降低患者血液中C反应蛋白水平的方法治疗COVID家族中的病毒疾病。